Strategies for better diabetes control in the US

Drugs

Volumn 58, Issue SUPPL. 1, 1999, Pages 61-69

  Garber, Alan J ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA; TROGLITAZONE;

ALGORITHM; BLOOD GLUCOSE MONITORING; CONFERENCE PAPER; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; UNITED STATES;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; TEXAS; UNITED STATES;

EID: 0032697355     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958001-00014     Document Type: Article

References (20)

1. Harris, MI, Cowie CC, Stern MP, et al. (editors). Diabetes in America. 2nd ed. NIH Publication No. 95-1468. Belhesda: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes Group Data Group, 1995
2. Market Measures Inc. Management of diabetes study XIII, Sep 1997
3. Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safely, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemie control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebocontrolled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997; 20: 597-606
4. Stenman S, Melander A, Groop P-H, et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-72
5. Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998; 13:173-80
6. Landgraf R, Bilbo H. Repaglinide vs glibenclamide: a 14-week efficacy and safety comparison. Diabetes 1997 May; 46 Suppl. 1: 162
7. Garber AJ, Duncan TO, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 102: 491-7
8. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9
9. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in diabetes mellitus. Drugs 1995; 49: 721-49
10. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-54
11. Balfour JA, Wilde MI. Management of type 2 diabetes: defining the role of acarbose. Dis Manage Health Outcomes 1997; 2: 248-60
12. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 1995; 18: 817-24
13. Plosker GL, Faulds D. Troglitazone: a review of its use in the manasement of type 2 diabetes mellitus. Drues 1999; 57: 409-38
14. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone, a new hypoglycemie agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151-6
15. Fonesca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemie control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 1998; 83: 3169-76
16. Garber AJ. Metformin therapy for type II diabetes mellitus. Pharm Ther 1995; 20 (Sep): 568-84
17. Kumar S, Boulton AJ, Beck-Nielsen H, et al. Troglitazone, an insulin enhancer, improves metabolic control in NIDDM patients. Troslitazone Study Group. Diabetologia 1996; 39: 701-9
18. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebocontrolled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-51
19. Data on file, Parke-Davis Co.
20. Data on file, Novo Nordisk Pharmaceuticals, Inc.